The clinical implication of tissue renin angiotensin systems

Current Opinion in Cardiology

Volumn 16, Issue 6, 2001, Pages 317-327

  Re, Richard N ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL TISSUE; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; HEART VENTRICLE REMODELING; HUMAN; HUMAN TISSUE; KIDNEY TUBULE EXCRETION; NONHUMAN; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRESSOR RESPONSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS;

BLOOD VESSELS; DIABETES MELLITUS, TYPE 2; HUMANS; KIDNEY; MYOCARDIUM; RENIN-ANGIOTENSIN SYSTEM;

EID: 0035214442     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200111000-00002     Document Type: Review

References (117)

1. The renin angiotensin system
2. Association of renin/sodium profile with risk of myocardial infarction in patients with hypertension
3. Is it time for a new approach to the initial treatment of hypertension
4. Improving prognosis in hypertension: Exploring the benefits of angiotensi II type I receptor blockade
5. The effect of angiotensin converting enzyme inhibition on diabetic Nnephropathy
6. Role of angiotensin-converting-enzyme inhibition in patients with renal disease
7. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
8. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy
9. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
10. Effect of Ccaptopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
11. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The heart outcomes prevention evaluation study snvestigators
12. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?
13. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer
14. New competition in the realm of renin-angiotensin axis inhibition: The angiotensin II receptor antagonists in congestive heart failure
15. Cellular biology of the renin angiotensin systems
16. Tissue angiotensin systems in cardiovascular medicine: A paradigm shift?
17. Renin is not synthesized by cardiac and extra renal vascular tissues: Review of experimental evidence
18. Renin activity content in various tissues of dogs under different physiopathological states
19. The brain renin-angiotensin system: Localization and general significance
20. Renin-containing muller cells of the retina display endocrine features
21. The ovary
22. Renin uterus and amniotic fluid
23. Definitive molecular evidence of renin-angiotensin system in human uterine decidual cells
24. Renin synthesis by cultured arterial smooth muscle cells
25. Evidence for the existence of renin in the heart
26. Cardiomyocytes bind and activate native prorenin: Role of soluble mannose 6-phosphate receptors
27. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding
28. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro
29. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure
30. Human spiral artery renin-angiotensin system
31. Induction of renin in medial smooth muscle cells by balloon injury
32. The Cardiac renin-angiotensin system: Conceptual, or regulator of cardiac function?
33. Renin expresssion at sites of repair in the infarcted rat heart
34. Distinct renin isoforms generated by tissue-specific transcription initiation and alternative splicing
35. An alternative transcript of the rat renin gene can result in a truncated prorenin that is transported into adrenal mitochondria
36. Tissue-specific expression of a rat renin transcript lacking the coding sequence for the prefragment and its stimulation by myocardial infarction
37. The nature of intracrine peptide hormone action
38. Losatan and angiotensin II inhibit aldosterone production in anephric rats via different actions on the intraadrenal renin-angiotensin system
39. Regulation of renin gene expression in rat adrenal glomerulosa cells
40. Angiotensinogen secretion by single rat pituitary cells: Detection by a reverse haemolytic plaque assay and cell identification by immunocytochemistry
41. Secretion of renin-angiotensin system (RAS) components by normal and tumoral lactotropes: A comparative study using reverse hemolytic plaque assay (RHPA)
42. Increased accumulation of tissue ACE in human atherosclerotic coronary disease
43. Tissue angiotensin and pathology of vascular disease: A unifying hypothesis
44. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart
45. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery
46. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
47. Chemistry of a human monocyte-derived cell (U937): Identification of the angiotensin I-converting activity as leukocyte cathepsin G
48. Phenotypic modulation by fibronectin enhances the angiotensin II-generating system in cultured vascular smooth muscle cells
49. Evidence that angiotensin II is present in human monocytes
50. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II
51. Characterization of renin activity in brown adipose tissue
52. Renin is expressed in rat macrophage/monocyte cells
53. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages
54. Rat epididymal fat tissue express all components of the renin-angiotensin-system
55. Localization of angiotensin messenger RNA in rat aorta
56. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems
57. Enzymatic reactions of the renin-angiotensin system
58. Cardiac renin and angiotensins: Uptake from plasma versus in situ synthesis
59. Circulating versus tissue angiotensin II
60. Inhibition of early atherosclerosis by losartan in monkeys with diet-induced hypercholesterolemia
61. AT(1) and AT(2) receptors in the kidney: Role in disease and treatment
62. Up-regulation of At-1 and At-2 receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell death
63. AT1-receptor heterodimers show enhanced G-Protein activation and altered receptor sequestration
64. Pathways of angiotensin (1-7) metabolism in the kidney
65. Cardiac aldosterone production and ventricular remodeling
66. Opposing actions of angiotensins on angiogenesis
67. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated receptor transactivation
68. Angiotensin induction of PAl-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
69. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes
70. Cardiac arrhythmias: The possible role of the renin-angiotensin system
71. Memory enhancement by the angiotensinergic system in the crab Chasmagnathus is mediated by endogenous angiotensin II
72. Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm
73. The effects of angiotensin IV analogues on long-term potentiation within the CA1 region of the hippocampus in vitro
74. A role for the renin-angiotensin system in the evolution of cardiac memory
75. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme
76. Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: Evidence for tissue angiotensin-converting enzyme function
77. Increased cardiac angiotesin II levels induce right and left ventricular hypertrophy in normotensive mice
78. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system
79. Angiotensin converting enzyme inhibition reduces neuroblastoma cell growth rate
80. The Interaction of insulin and angiotensin II on the regulation of human neuroblastoma cell growth
81. The use of antisense oligonucleotides to establish autocrine angiotensin growth effects in human neuroblastoma and mesangial cells
82. The paradox of the low-renin state in diabetic nephropathy
83. Renal vascular responses to captopril and to candesartan in patients with type I diabetes mellitus
84. Renal actions of angiotensin II and AT1 receptor blockers
85. Insulin and insulin-like growth factor promotes angiotensinogen production and growth in vascular smooth muscle cells
86. Intrarenal angiotensin II augmentation in angiotensin II dependent hypertension
87. Subcellular localization of angiotensin II in kidney and adrenal
88. RENAAL and IDNT studies
89. The Val-HeFT trial
90. Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE)
91. Influence of the status of the renin- angiotensin system on the effects of cilazapril on neointima formation after vascular injury in rats
92. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
93. Lesser responses to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction
94. Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure
95. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function
96. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients
97. Early, short-term treatment with captopril permanently attenuates cardiovascular changes in spontaneously hypertensive rats
98. Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis
99. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibiton by angiotensin II type 1 receptor antagonist
100. Renin in blood vesssels in human pulmonary tumors. An immunohistochemical and biochemical study
101. Renin in acute myeloid leukaemia blasts Br
102. Identification and antisense inhibition of a renin-angiotensin system in transgenic cardiomyocytes
103. The mas oncogene enhances angiotensin-induced (Ca+2)responses in cells with pre-existing angiotensin II receptors
104. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The captopril prevention project (CAPPP) randomized trial
105. Blockade of angiotensin converting enzyme but not of angiotensin AT 1 receptors improves glucose tolerance
106. Bradykinin may not be involved in improvement of insulin resistance by angiotensin converting enzyme inhibitor
107. The effect of angiotensin II receptor antagonist with losartan on glucose metabolism and insulin sensitivity
108. A comparison of the hypotensive and hypoglycemic actions of an angiotensin converting enzyme inhibitor, an AT1 a antagonist and troglitazone
109. Diabetes, hypertension, and cardiovascular disease
110. Prorenin processing by cathepsin B in vitro and in transfected cells
111. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis
112. Local renin-angiotensin system in human adrenals and aldosteronomas
113. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes
114. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia
115. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence
116. Local renin-angiotensin systems